US vs non-US Retreatment Rates After Intravitreal Anti-VEGF Injections for ROP.

IF 4.4 Q1 OPHTHALMOLOGY

Ophthalmology. Retina Pub Date : 2025-03-23 DOI:10.1016/j.oret.2025.03.013

Nimesh A Patel, Luis A Acaba-Berrocal, Sandra Hoyek, Celine Chaaya, Kenneth C Fan, Maria Ana Martinez-Castellanos, Caroline R Baumal, C Armitage Harper, Audina M Berrocal

引用次数: 0

Abstract

This multicenter study determines the differences in retreatment rates after intravitreal anti-VEGF treatment for Retinopathy of Prematurity between the United States (US) and non-US sites. Ranibizumab was associated with significantly more retreatment compared to bevacizumab.

查看原文本刊更多论文

玻璃体内注射抗vegf治疗ROP后的美国和非美国再治疗率。

这项多中心研究确定了美国和非美国地区早产儿视网膜病变玻璃体内抗vegf治疗后复治率的差异。与贝伐单抗相比，雷尼单抗与更多的再治疗相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊